Trevi Therapeutics, Inc.
NASDAQ: TRVI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jennifer L. Good
- Employees
- 31
- Headquarters
- New Haven, United States
- IPO year
- 2019
- Market cap
- $2.5B
- Website
- https://www.trevitherapeutics.com
Loading TRVI…
Loading profile data…Frequently asked questions about TRVI
What does Trevi Therapeutics, Inc. (TRVI) do?
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruri...
Where does TRVI trade?
Trevi Therapeutics, Inc. (TRVI) trades on the NASDAQ Global Market.
What sector is TRVI in?
Trevi Therapeutics, Inc. (TRVI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Trevi Therapeutics, Inc.?
Jennifer L. Good is the chief executive officer of Trevi Therapeutics, Inc. (TRVI).
Where is Trevi Therapeutics, Inc. headquartered?
Trevi Therapeutics, Inc. is headquartered in United States.
Does TRVI pay a dividend?
Trevi Therapeutics, Inc. (TRVI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TRVI go public?
Trevi Therapeutics, Inc. (TRVI) completed its initial public offering in 2019.